Deals & Cases

Schellenberg Wittmer advises Santhera on license for North America for Vamorolone


Santhera Pharmaceuticals (SIX: SANN) has signed an exclusive license and collaboration agreement for vamorolone in North America (NA) with Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX).

The agreement covers commercialization of vamorolone in Duchenne Muscular Dystrophy and rights to all potential future indications in North America. Total consideration to Santhera is up to USD 231 million (including equity investment), plus royalty payments from product sales, with near term cash proceeds for Santhera of USD 126 million.

Schellenberg Wittmer advised Santhera on the license agreement. The team included Philipp Groz and Alisa Zehner (both IP / Life Sciences), Marcel Jakob (Corporate/M&A), Michael Nordin and Tabea Elmer (both Tax).


Stay up to date!

*Required fields

Newsletters & Newsflashes

Monthly selected key topics from our practice areas, sectors and industries, plus newsflashes on recent developments.


Monthly email with the latest updates and summaries of the Swiss Federal Supreme Court's case law in arbitration matters.
Regular insights into Swiss and international trends and legal developments in the construction industry.
Regular insights and updates on key developments in the rapidly changing landscape of Environmental, Social and Corporate Governance disputes.
Concise analysis of key trends in the fast-moving world of corporate governance for board members of Swiss companies.
A regular look from a unique M&A perspective at legal changes, economic developments and societal trends in Switzerland.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.